Cutaneous Melanoma and Sentinel Lymph Node Biopsy; An Epidemiology Study of Population Level Data

Aims Cutaneous melanoma accounts for 90% of all melanoma cases diagnosed. In addition, the incidence of cutaneous melanoma is increasing by approximately 3-7% yearly, and it is the most rapidly increasing cancer diagnosed in white populations worldwide. The aim of this study is to assess the survival benefit of Sentinel Lymph Node Biopsy (SLNB) in cutaneous melanoma in an Irish population. Methods Population based data was obtained from the National Cancer Registry of Ireland (NCRI) on all patients with a cutaneous melanoma diagnosed over a 20-year period 1994-2014 and predictors of Overall Survival (OS) were assessed. Results 13302 patients were identified with a melanoma diagnosis between 1994-2014. OS varied with gender, age, smoking and marital status, anatomical location and TMN stage. 2196 (17%) patients underwent SLNB, which included 710 patients in the stage 1 melanoma category (<11% of this group). Undergoing a SLNB was not an independent predictor of improved OS (p=0.440). However, a positive SLNB result was an independent predictor of OS (0.001). Conclusion This Irish population-based data re-affirms demographic indicators of poorer survival. A positive SLNB result indicates poorer survival; however, the precedent itself is not a predictor of OS.